/**/ document.writeln("\n\n\n\n\n \n\n\n\n\n \n \n \n\n
\n\n \n
\n \n \n \n \n
 Recent News for Chelsea Therapeutics International Ltd.\n \n\n\n\n\n
Nov 22 7:50 AM EST
\n\n\n\n
\n \n
\n \n \n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n
\n\n Nov 12, 2009 7:36 AM EST
\n\n \n Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 20th Annual International Symposium on the Autonomic Nervous System - GlobeNewswire\n \n \n
\n\n Nov 02, 2009 4:16 PM EST
\n\n \n Chelsea Therapeutics Reports Third Quarter 2009 Results - GlobeNewswire\n \n \n
\n\n Nov 02, 2009 7:30 AM EST
\n\n \n Chelsea Therapeutics Appoints Dr. William D. Schwieterman Chief Medical Officer - GlobeNewswire\n \n \n
\n\n Oct 28, 2009 9:05 AM EDT
\n\n \n Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2009 Results - GlobeNewswire\n \n \n
\n\n Oct 27, 2009 7:31 AM EDT
\n\n \n Chelsea Therapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, 2009 - GlobeNewswire\n \n \n
\n\n Oct 20, 2009 7:31 AM EDT
\n\n \n Chelsea Therapeutics Presents Novel, Metabolically Inert Autoimmune Portfolio at the 2009 ACR Annual Scientific Meeting - GlobeNewswire\n \n \n
\n\n Oct 01, 2009 4:01 PM EDT
\n\n \n Chelsea Therapeutics to Host Conference Call to Discuss Droxidopa Phase III Results Today At 4:30 PM ET - GlobeNewswire\n \n \n
\n
\n\n");